Goldman Sachs International Equity Insights is a true quant fund run by a talented, well-resourced team. Higher conviction in its exhaustive quantitative approach earns it a Process rating upgrade to Above Average from Average. It is an overall good option for investors seeking international exposure.
Goldman Sachs International Equity Insights Fund Class C GCICX
- NAV / 1-Day Return 19.42 / +0.05 %
- Total Assets 6.8B
-
Adj. Expense Ratio
1.910%
- Expense Ratio 1.910%
- Distribution Fee Level Above Average
- Share Class Type Level Load
- Category Foreign Large Blend
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.81%
- Turnover 156%
USD | NAV as of Jun 17, 2026 | 1-Day Return as of Jun 17, 2026, 12:11 AM GMT+0
Morningstar’s Analysis GCICX
Will GCICX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the GCICX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of GCICX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 16.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
ASML Holding NV | 3.27 | 182M | Technology |
Nestle SA | 2.21 | 124M | Consumer Defensive |
Allianz SE | 1.81 | 101M | Financial Services |
ABB Ltd | 1.62 | 90M | Industrials |
Sanofi SA | 1.44 | 80M | Healthcare |
Roche Holding AG Ordinary Shares new | 1.34 | 75M | Healthcare |
Nordea Bank Abp | 1.33 | 74M | Financial Services |
Takeda Pharmaceutical Co Ltd | 1.30 | 73M | Healthcare |
Novartis AG Registered Shares | 1.26 | 71M | Healthcare |
AstraZeneca PLC ADR | 1.19 | 67M | Healthcare |
United States